Primary brain tumours (gliomas) initiate a strong host response and can contain large
amounts of immune cells (myeloid cells) such as microglia and tumour-infiltrating …

Despite advances in treatment regimens that comprise surgery, chemotherapy, and
radiation, outcome of many brain tumors remains dismal, more so when they recur. The …

The use of inhibitory checkpoint blockade in the management of glioblastoma has been
studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently …

We characterized GBM patients' tumor and systemic immune contexture with aim to reveal
the mechanisms of immunological escape, their impact on patient outcome, and identify …

Glioblastoma multiforme (GBM) is an aggressive malignancy associated with profound host
immunosuppression mediated in part by FoxP3 expressing regulatory CD4+ T lymphocytes …

Forkhead box P3 (Foxp3)+ regulatory T (Treg) cells maintain the immune tolerance and
prevent inflammatory responses in the periphery. However, the presence of Treg cells in the …

Glioma stem cells (GSCs) contribute to the malignant growth of glioma, but little is known
about the interaction between GSCs and tumor microenvironment. Here, we found that …

Purpose: This study is directed at identifying the cell source (s) of immunomodulatory
cytokines in high-grade gliomas and establishing whether the analysis of associated …

Glioblastoma multiforme (GBM) is a devastating tumour with abysmal prognoses. We
desperately need novel approaches to understand GBM biology and therapeutic …

Background Glioma-related immunosuppression is well documented; however, the
mechanisms of suppression are not fully understood. Here we explore a role for glioma …